Dr Reddy’s Laboratories has launched Paricalcitol capsules, 1mcg, 2mcg and 4mcg, a therapeutic equivalent generic version of ZEMPLAR Paricalcitol capsules in the US market on June 24, following the approval by the United States Food & Drug Administration (USFDA). These capsules will be available in a bottle in counts of 30.
The Zemplar brand and generic had US sales of approximately $109 million MAT for the most recent twelve months ending March 2014 according to IMS health.
Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
